1) Uchiyama T, et al : Adult T-ce111eukemia : clinical and hematologic features of 16 cases. Blood 50 : 481-492, 1977.
2) Hinuma Y, et al : Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78 : 6476-6480, 1981.
3) Osame M, et al : HTLV-I associated myelopathy, a new clinical entity. Lancet i : 1031-1032, 1986.
4) Gessain A, et al : Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii : 407-410, 1985.
5) Hino S : Primary prevention of adult T cell leukemia (ATL) in Nagasaki, Japan by refraining from breast-feeding. In : Gann Monograph on Cancer Research, Vol 50 (ed by Sugamura K, et al), p 241-251, Japan Science Societies Press, Tokyo, 2003.
6) Manel N, et al : The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115 : 449-459, 2003.
7) Sagara Y, et al : 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic Virus type 1. J Virol 72 : 535-541, 1998.
8) Pinon JD, et al : Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 77 : 9922-9930, 2003.
9) Tajima K : The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan : estimates of risk of ATL and its geographical and clinical features. The T-and B-cell Malignancy Study Group. Int J Cancer 45 : 237-243, 1990.
10) Hisada M, et al : Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus type I carriers in Japan. Int J Cancer 77 : 188-192, 1998.
11) Hasegawa A, et al : Expansion of human T-cell leukemia virus type 1 (HTLV-I) reservoir in orally infected rats : Inverse correlation with HTLV-I-specific cellular immune response. J Virol 77 : 2956-2963, 2003.
12) Usuku K, et al : HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy : comparison with adult T-cell leukemia/lymphoma. Ann Neurol 23 (Suppl) : S143-150, 1988.
13) Furukawa Y, et al : Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-I)-infected T cells in HTLV-I-associated myelopathy (HAM-TSP). Blood 80 : 1012-1016, 1992.
14) Yoshida M : Multiple viral strategies of HTLV-I for dysregulation of cell growth control. Annu Rev Immunol 19 : 475-496, 2001.
17) Mori N, et al : Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93 : 2360-2368, 1999.
19) Kannagi M, et al : Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol 3 : 761-767, 1991.
20) Kannagi M, et al : Expression of the target antigen for cytotoxic T lymphocytes on adult T-cel1-leukemia cells. Int J Cancer 54 : 582-588, 1993.
21) Ohashi T, et al : Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T cell leukemia virus type 1-immortalized cells. J Virol 73 : 6031-6040, 1999.
22) Ohashi T, et al : Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol 74 : 9610-9616, 2000.
23) Hanabuchi S, et al : Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model : peptide-induced T-cell immunity. J Natl Cancer Inst 93 : 1775-1783, 2001.
24) Arnulf B, et al : Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 18 : 126-132, 2004.
27) Ishiguro N, et al : A rat model of human T lymphocyte virus type I (HTLV-I) infection. 1. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats. J Exp Med 176 : 981-989, 1992.
28) Kubota R, et al : HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol 102 : 208-215, 2000.
29) Bangham CR : The immune response to HTLV-I. Curr Opin Immunol 12 : 397-402, 2000.
30) Tsukasaki K, et al : Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77 : 164-170, 2003.
36) Nasr R, et al : Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-I-infected leukemic cells. Blood 101 : 4576-4582, 2003.
37) Waldmann TA, et al : Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86 : 4063-4075, 1995.
38) Taylor GP, et al : Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-I) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-I-associated myelopathy. J Virol 73 : 10289-10295, 1999.
39) Izumo S, et al : Interferon-alpha is effective in HTLV-I-associated myelopathy : a multicenter, randomized, double-blind, controlled trial. Neurology 46 : 1016-1021, 1996.
40) Broder CC, Collman RG : Chemokine receptors and HIV. J Leukoc Biol 62 : 20-29, 1997.
41) Geijtenbeek TB, et al : DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 : 587-597, 2000.
42) Paxton WA, et al : Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 2 : 412-417, 1996.
43) Kaul R, et al : HIV-1-specific mucosal CD8+ lymphocyte responses in the cerviX of HIV-1-resistant prostitutes in Nairobi. J Immunol 164 : 1602-1611, 2000.
44) Stranford SA, et al : Lack of infection in HIV-exposed individuals is associated with a strong CD8 (+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 96 : 1030-1035, 1999.
45) Koup RA, et al : Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 : 4650-4655, 1994.
46) Lefrere JJ, et al : The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 177 : 1541-1548, 1998.
48) Rosenberg ES, et al : Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 : 1447-1450, 1997.
49) Levy JA : The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 24 : 628-632, 2003.
50) Kestler HW, et al : Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65 : 651-662, 1991.
51) Salghetti S, et al : Human immunodeficiency virus type 1 Nef and p561ck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail. Proc Natl Acad Sci USA 92 : 349-353, 1995.
53) Mueller YM, et al : Increased CD95/Fas-induced apoptosis of HIV-specific CD8 (+) T cells. Immunity 15 : 871-882, 2001.
54) Carrington M, et al : HLA and HIV-1 : heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 : 1748-1752, 1999.
55) Kubo M, et al : Abrogation of in vitro suppression of human immunodeficiency virus type 1 (HIV-1) replication mediated by CD8+ Tlymphocytes of asymptomatic HIV-1 carriers by staphylococcal enterotoxin B and phorbol esters through induction of tumor necrosis factor alpha. J Virol 71 : 7560-7566, 1997.
56) Wong JK, et al : Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 : 1291-1295, 1997.
59) French MA, et al : Immune restoration disease after antiretroviral therapy. AIDS 18 : 1615-1627, 2004.